Despite the Use of the Combination of G-CSF and Plerixafor for Stem Cell Mobilization, One Third of the Patients with Lymphoma Were Still “Poor Mobilizer” Using the Criteria Recently Proposed by GITMO (< 2.0 X 106 CD 34 + Cells Per Kg in ≤ 3 Apheresis)  by Fung, H.C. et al.
Poster Session I S263PFS (53% vs 13%, p5 0,004). Day 100 chimerism does not predict
incidence of cGVHD, relapse, or overall survival. Day 56 chimerism
result was higher for patient who experienced aGVHD (median 89%
vs 78%, p 5 0,048) and was associated with better OS if less than
82.5% (84% vs 53%, p 5 0,01).
Conclusion: Limiting CD34 cell dose could lower incidence of
cGVHD presumably without influencing relapse incidence and
overall survival, while limiting CD3 cell dose could improve survival.
Early evaluation of chimerism at day 56 is relevant to identify pa-
tients who will experience aGVHD and predict survival.160
STEM CELL TRANSPLANT ADVERSE REACTIONS (STAR) ANALYSIS: DOES
A HIGHER INFUSION RED BLOOD CELL CONTENT CORRELATE WITH SE-
RIOUS ADVERSE EVENTS?
Vidula, N., Villa, M., Mehboob, M., Jovanovic, B., Meagher, R.,
Gordon, L.I. Northwestern University Feinberg School of Medicine, Chi-
cago, IL
Introduction: Stem cell transplantation has emerged as a treatment
option for patients with hematologic malignancies. With transplan-
tation, however, there is a risk of adverse events associated with the
stem cell infusion. These events were previously attributed to the
cryoprotectant used in cell preparation, but the persistence of these
events with cryoprotectant depletion suggests the involvement of
other factors. Recently, the red blood cell content of stem cell infu-
sions has been implicated in transplant related adverse events includ-
ing bradycardia and renal toxicity. We analyzed the Northwestern
University transplant experience to determine whether the red blood
cell content of an infusion correlated with serious adverse reactions
such as stroke and seizure.
Methods:We conducted a retrospective chart review of all hemato-
logic malignancy patients at our center who received stem cell trans-
plants between 1/1/08 and 5/1/11. Detailed patient and infusion
characteristics were collected.
Results: We identified 462 hematologic malignancy patients who
received stem cell transplants. The mean red blood cell content
per kilogram body weight of the stem cell infusion for the entire pop-
ulation was 0.25mL/kg6 .34 (range 0.02-4.32mL/kg). Five patients
had serious adverse reactions including stroke (3 patients), seizure (1
patient), and nausea, vomiting, and flushing (1 patient). The mean
red blood cell content per kilogram body weight of the stem cell in-
fusion for these 5 patients with serious adverse events was 0.34 mL/
kg 6 0.20 (range 0.13-0.63).
Conclusions: Our preliminary results suggest that serious adverse
events at the time of stem cell transplantation are generally rare, but
can be devastating. We note a slightly higher red blood cell content
amongst those patients experiencing these types of events compared
to the study population as a whole. However, further study is ongoing
to determine whether there is a correlation between RBC content and
serious adverse events at the time of stem cell re-infusion.161
DESPITE THE USE OF THE COMBINATION OF G-CSF AND PLERIXAFOR
FOR STEM CELL MOBILIZATION, ONE THIRD OF THE PATIENTS WITH
LYMPHOMA WERE STILL ‘‘POOR MOBILIZER’’ USING THE CRITERIA
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Background: Gruppo Italian Trapianto di Midollo Osseo
(GITMO) recently proposed a new definition on ‘‘poor mobilizer’’
based on G-CSF (G) +/- chemotherapy based mobilization strategy
(BMT (2011), 1-10). Data on using the combination of G + plerixa-
for (P) for mobilization (Mob) were however not utilized to formu-
late this proposal. Method: In this retrospective analysis, we
examined the Mob kinetic, incidence and characteristics of ‘‘poormobilizer’’ as proposed by GITMO in pts receving G + P for mob.
Between 02/09 & 05/10, 58 consecutive pts with NHL, HD, or
MM underwent Stem Cell Mobilization at our instituion using the
combinaiton of G + P.Mob consisted ofG-CSF 10 mg/kg SC admin-
istered daily at 6:00 am on days 1 through 4 plus plerixafor 0.24 mg/
kg SC given once daily at 5:00 pm in an outpatient clinic beginning
on day 4. Thirty-one (53%) pts had lymphoma (28NHL& 3HD)&
27 (47%) patients had MM. The median age was 57.3 years (range,
30.4-71.1). At the time of mob, all pts except 3 (5%) had chemo-re-
sponsive disease. One third of pts had received. 2 prior chemother-
apy regimens and nearly half (43%) had received prior radiation
therapy. Seven (12%) pts (4 NHL and 3 MM) had undergone previ-
ous mob attempts that did not include P.
Results:Themedian totalCD34+ cell yields were 3.06 106 and 8.27
 106 CD34+ cells/kg for lymphoma and myeloma pts, respectively.
Apheresis yielded an adequate number of CD34+ cells in a median
of 2 days (range, 1-4). The minimum CD34+ cell yield (2  106
CD34+ cells/kg for lymphoma pts; 4  106 CD34+ cells/kg for mye-
loma pts was achieved in 45 (78%) pts, including 23 (74%) lymphoma
and 22 (81%)myeloma patients. 26 of 27 (96%)myeloma pts achieved
yields of$2 x 106 CD34+ cells/kg. 30 (52%) pts (14 [45%] lymphoma;
16 [59%] myeloma) achieved their respective minimum CD34+ cell
yields within 1 apheresis day. On the other hand, 12 (39%) pts with
lymphoma and 1 (4%) pt with myeloma were identified as poor mobi-
lizer using the criteria proposed byGITMO.Advanced disease, refrac-
tory disease, extensive BM involvement or cellularity\ 30% and age
. 65 did not predict for poor mobilization.
Conclusion:Weconclude that despite the use ofG-CSF+P, one third
of the pts with lymphoma are still ‘‘poormobilizer’’ and larger study will
be required to identify predictors for poormobilization for pts usingG-
CSF + P as mobilization strategy. Additional measures are required to
further improve mobilization efficiency for lymphoma pts.162
ANALYSIS OF INF-g AND TNF-a, CXCL-10 CHEMOKINE AND ITS RECEP-
TOR CXCR-3 EXPRESSION IN SKIN BIOPSIES FROM PATIENTS WITH
ACUTE GRAFT-VERSUS-HOST DISEASE
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Introduction: Acute graft-versus-host disease (aGVHD) is one of
the most frequent complications in patients undergoing allogenic
hematopoietic stem cell transplantation (HSCTs), occurring in
35% to 50% of cases. The pathophysiology of this disease is charac-
terized by immunological factors causing tissue injury in various or-
gans such as skin, liver and gastrointestinal tract. The skin is usually
the initial target of the disease, and also the organ most affected. Cy-
tokines and chemokines participate in several important inflamma-
tory processes and has been described as important molecules in
the development of aGVHD.
Objective: Evaluate the expression profile of cytokines INF-g and
TNF-a, the chemokine CXCL-10 and its receptor CXCR-3 in
skin biopsies of patients undergoing allogeneic HSCT who devel-
oped or not aGVHD in skin.
Material andMethods:We analyzed by immunohistochemistry, 32
skin biopsies of patients undergoing allogeneic HSCT at the Bone
Marrow Transplantation Center (CEMO-INCA) (24 with and 08
without aGVHD) on day D-8, D0, D +14, D +28 and D +100.
Skin biopsies of healthy donors were used as control.
Results: The labeling of INF-g and TNF-a, CXCL-10 and CXCR-3
in skin biopsies of patientswhohad aGVHDornot remained at the level
of the basal layer of epidermis. However, there was an increased expres-
sion of these molecules in all patients assessed when compared with the
level of expression in skin biopsies of healthy donors. In addition, no sig-
nificant differences were found when comparing the level of expression
of these molecules in pre-HSCT (day D-8) with the day of diagnosis.
Conclusion: These results suggest that the expression of cytokines
INF-g and TNF-a, CXCL-10 chemokine and its receptor CXCR-
3 in skin biopsies of patients does not appear to be related to aGVHD
but with procedures related to transplantation.
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